Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Retained Earnings (2016 - 2025)

Gsk has reported Retained Earnings over the past 11 years, most recently at $1.8 billion for Q4 2025.

  • Quarterly results put Retained Earnings at $1.8 billion for Q4 2025, down 82.44% from a year ago — trailing twelve months through Dec 2025 was $1.8 billion (down 82.44% YoY), and the annual figure for FY2025 was $1.8 billion, down 82.44%.
  • Retained Earnings for Q4 2025 was $1.8 billion at Gsk, down from $10.0 billion in the prior quarter.
  • Over the last five years, Retained Earnings for GLAXF hit a ceiling of $10.0 billion in Q4 2024 and a floor of $516.3 million in Q4 2021.
  • Median Retained Earnings over the past 5 years was $1.8 billion (2025), compared with a mean of $3.3 billion.
  • Biggest five-year swings in Retained Earnings: surged 278.68% in 2024 and later crashed 82.44% in 2025.
  • Gsk's Retained Earnings stood at $516.3 million in 2021, then skyrocketed by 228.96% to $1.7 billion in 2022, then soared by 55.58% to $2.6 billion in 2023, then surged by 278.68% to $10.0 billion in 2024, then crashed by 82.44% to $1.8 billion in 2025.
  • The last three reported values for Retained Earnings were $1.8 billion (Q4 2025), $10.0 billion (Q4 2024), and $2.6 billion (Q4 2023) per Business Quant data.